Prognostic Nomograms Based on Ground Glass Opacity and Subtype of Lung Adenocarcinoma for Patients with Pathological Stage IA Lung Adenocarcinoma

被引:5
|
作者
Zhai, Wenyu [1 ]
Liang, Dachuan [1 ]
Duan, Fangfang [2 ]
Wong, Wingshing [1 ]
Yan, Qihang [3 ]
Gong, Li [1 ]
Lai, Renchun [4 ]
Dai, Shuqin [5 ]
Long, Hao [1 ]
Wang, Junye [1 ]
机构
[1] Sun Yat Sen Univ, Dept Thorac Surg, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Dept Med Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
[3] Zhejiang Univ, Dept Thorac Surg, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
[4] Sun Yat Sen Univ, Dept Anaesthesiol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Dept Lab Med, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
关键词
lung adenocarcinoma; pathological subtype; GGO (ground glass opacity); nomogram; prognosis; PREDOMINANT HISTOLOGIC SUBTYPE; FACTOR RECEPTOR MUTATION; EGFR MUTATION; INTERNATIONAL ASSOCIATION; FREE SURVIVAL; CLASSIFICATION; CANCER; MICROPAPILLARY; IMPACT; CT;
D O I
10.3389/fcell.2021.769881
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The value of lung adenocarcinoma (LUAD) subtypes and ground glass opacity (GGO) in pathological stage IA invasive adenocarcinoma (IAC) has been poorly understood, and reports of their association with each other have been limited. In the current study, we retrospectively reviewed 484 patients with pathological stage IA invasive adenocarcinoma (IAC) at Sun Yat-sen University Cancer Center from March 2011 to August 2018. Patients with at least 5% solid or micropapillary presence were categorized as high-risk subtypes. Independent indicators for disease-free survival (DFS) and overall survival (OS) were identified by multivariate Cox regression analysis. Based on these indicators, we developed prognostic nomograms of OS and DFS. The predictive performance of the two nomograms were assessed by calibration plots. A total of 412 patients were recognized as having the low-risk subtype, and 359 patients had a GGO. Patients with the low-risk subtype had a high rate of GGO nodules (p < 0.001). Multivariate Cox regression analysis showed that the high-risk subtype and GGO components were independent prognostic factors for OS (LUAD subtype: p = 0.002; HR 3.624; 95% CI 1.263-10.397; GGO component: p = 0.001; HR 3.186; 95% CI 1.155-8.792) and DFS (LUAD subtype: p = 0.001; HR 2.284; 95% CI 1.448-5.509; GGO component: p = 0.003; HR 1.877; 95% CI 1.013-3.476). The C-indices of the nomogram based on the LUAD subtype and GGO components to predict OS and DFS were 0.866 (95% CI 0.841-0.891) and 0.667 (95% CI 0.586-0.748), respectively. Therefore, the high-risk subtype and GGO components were potential prognostic biomarkers for patients with stage IA IAC, and prognostic models based on these indicators showed good predictive performance and satisfactory agreement between observational and predicted survival.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Predicting the invasiveness of ground-glass opacity predominant lung adenocarcinoma with clinical stage Ia: a CT-based semantic and radiomics analysis
    Zhao, Yunqing
    Ye, Zhaoxiang
    Yan, Qingna
    Sun, Haoran
    Zhao, Fengnian
    JOURNAL OF THORACIC DISEASE, 2024, 16 (10)
  • [22] Effects of a ground-glass opacity component on the recurrence and survival of pathological stage IA3 lung adenocarcinoma: a multi-institutional retrospective study
    Xu, Shao-Jun
    Chen, Rui-Qin
    Tu, Jia-Hua
    You, Cheng-Xiong
    Chen, Chao
    Zhang, Zhi-Fan
    Divisi, Duilio
    Migliore, Marcello
    Bongiolatti, Stefano
    Durand, Marion
    Sato, Masaaki
    Kuroda, Hiroaki
    Yang, Chao-Fu
    Yu, Shao-Bin
    Chen, Shu-Chen
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (05) : 1078 - +
  • [23] Resected lung adenocarcinoma with lymph node metastasis: is ground glass opacity component a prognostic factor?
    Den, Chaoqiang
    Jiang, Chenyu
    Ma, Xiangyi
    Fu, Fangqiu
    Wang, Shengping
    Li, Yuan
    Zhang, Yang
    Chen, Haiquan
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (07) : 1609 - 1619
  • [24] Ground glass opacity and T-factor in staging lung adenocarcinoma
    Baisi, Alessandro
    De Simone, Matilde
    Raveglia, Federico
    Cioffi, Ugo
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2013, 43 (06) : 1271 - 1271
  • [25] THE ROLE OF THE GROUND-GLASS OPACITY RATIO IN RESECTED LUNG ADENOCARCINOMA
    Huang, Tsai-Wang
    RESPIROLOGY, 2018, 23 : 70 - 71
  • [26] The role of the ground-glass opacity ratio in resected lung adenocarcinoma
    Huang, Tsai-Wang
    Lin, Kuan-Hsun
    Huang, Hsu-Kai
    Chen, Yi-I
    Ko, Kai-Hsiung
    Chang, Cheng-Kuang
    Hsu, Hsian-He
    Chang, Hung
    Lee, Shih-Chun
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2018, 54 (02) : 229 - 234
  • [27] Genetic characteristics of lung adenocarcinoma with ground-glass opacity component
    Zhu, Weipeng
    Bai, Na
    Cao, Jiashun
    Yang, Fan
    Chen, Donghong
    JOURNAL OF THORACIC DISEASE, 2023, 15 (11) : 6106 - 6114
  • [28] Appropriate Sublobar Resection Choice for Ground Glass Opacity-Dominant Clinical Stage IA Lung Adenocarcinoma Wedge Resection or Segmentectomy
    Tsutani, Yasuhiro
    Miyata, Yoshihiro
    Nakayama, Haruhiko
    Okumura, Sakae
    Adachi, Shuji
    Yoshimura, Masahiro
    Okada, Morihito
    CHEST, 2014, 145 (01) : 66 - 71
  • [29] Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma
    Ohno, Takashi
    Kubouchi, Yasuaki
    Wakahara, Makoto
    Nosaka, Kanae
    Sakabe, Tomohiko
    Haruki, Tomohiro
    Miwa, Ken
    Taniguchi, Yuji
    Nakamura, Hiroshige
    Umekita, Yoshihisa
    ANTICANCER RESEARCH, 2018, 38 (05) : 3001 - 3007
  • [30] Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma
    Ohno, T.
    Nosaka, Y.
    Fujiwara, W.
    Miyamoto, T.
    Kadonaga, T.
    Kidokoro, Y.
    Wakahara, M.
    Takagi, Y.
    Tanaka, Y.
    Haruki, T.
    Miwa, K.
    Suzuki, Y.
    Taniguchi, Y.
    Nakamura, H.
    Umekita, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S770 - S771